Navigation Links
AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia
Date:8/17/2009

QUEBEC CITY, Aug. 17 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported Phase 3 results for its North American efficacy trial Z-033 and the safety trial Z-041 in benign prostatic hyperplasia (BPH), with its lead endocrinology compound for urology, cetrorelix pamoate. As announced on March 6, 2009, sanofi-aventis U.S. LLC entered into an agreement with AEterna Zentaris for the development, registration and marketing of cetrorelix in BPH for the U.S. market.

Study Z-033

The first multi-center efficacy trial Z-033 was conducted in 53 sites in the United States and Canada, with 8 additional sites in Europe. The study involved 667 patients under the supervision of lead investigator, Herbert Lepor, M.D., Professor and Chairman, Department of Urology, at NYU School of Medicine, New York. Patients entered a 1- to 4-week screening period to confirm severity and stability of voiding symptoms based on the International Prostate Symptom Score (IPSS). Patients were then randomly allocated to cetrorelix or placebo in a double-blind fashion. Patients were administered cetrorelix by intra-muscular (IM) injection at Week 0, 2, 26 and 28 (for treatment Arm A, those in Arm B received IM injection at week 0, 2 and 26 followed by placebo at Week 28). Patients in treatment Arm C received placebo injections at Week 0, 2, 26 and 28. All patients were followed up to Week 52.

The study Z-033 demonstrated no clear differences in overall efficacy with all 3 groups showing an improvement in IPSS of approximately 4 points that was maintained throughout the 52 weeks. There was a slight advantage in favor of the main active treatment arm (Arm A) up to Week 46 of the follow-up, which was no longer de
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results
2. AEterna Zentaris to Present at Upcoming Canaccord Adams 29th Annual Global Growth Conference
3. AEterna Zentaris to Announce Second Quarter 2009 Financial and Operating Results on August 11, 2009
4. AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
5. AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction
6. AEterna Zentaris Receives US$10 Million from Institutional Investors
7. AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule
8. AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia
9. AEterna Zentaris Discloses Preliminary Phase 2 Trial Results for Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer
10. AEterna Zentaris Acquires All Assets from Ardana for Growth Hormone Secretagogue Compound, AEZS-130
11. AEterna Zentaris Presents Data Supporting Evaluation of AEZS-108 in Prostate Cancer at ASCO Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... (PRWEB) July 31, 2014 Food ... are increasingly searching for food alternatives that offer ... benefits. The food ingredient market has numerous players ... such as Vital Force Technology (VFT). VFT ... than 4,000 energetic patterns, all tested to produce ...
(Date:7/31/2014)... , July 31, 2014 Nearly 20,000 ... th Annual Meeting & Clinical Lab Expo in ... meeting featured never-before-seen breakthroughs in diagnostic research and technology ... they need. As of Wednesday, July 30, ... AACC Annual Meeting & Clinical Lab Expo, with more ...
(Date:7/31/2014)... through organs and even the entire body to visualize ... structures has been a long-time dream of biologists. A ... in the journal Cell has now made ... opaque organs, bodies, and human tissue biopsies transparent, while ... could pave the way for a better understanding of ...
(Date:7/31/2014)... July 31, 2014 The SNIS Foundation ... $25,000 to fund a translational research project.  The ... the gift was presented at the Society of ... in Colorado Springs, CO. ... approaches to neurovascular conditions, SNIS formed the SNIS ...
Breaking Biology Technology:Functional Ingredient Manufacturer – Vital Force Technology Infuses Raw Materials & Ingredients with Subtle Energy Formula 2Research on Digital Health, Alzheimer's, Ebola Draws Nearly 20,000 Attendees to 2014 AACC Annual Meeting & Clinical Lab Expo 2Research on Digital Health, Alzheimer's, Ebola Draws Nearly 20,000 Attendees to 2014 AACC Annual Meeting & Clinical Lab Expo 3See-through organs and bodies will accelerate biomedical discoveries 2SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 2SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 3
... , , SAN ... (NYSE: SAI ) announced today that Anthony Hess, Ph.D., ... Health Solutions BU (HSBU) effective Aug. 3. Hess will ... and commercial health customers, including the Departments of Defense, Health and ...
... PERTH, Australia, July 16 Dow AgroSciences LLC, a wholly owned ... and NemGenix, a Perth based biotechnology company, announced today a newly ... , , The collaboration will ... Financial terms of the agreement were not disclosed. , ...
... , COSTA MESA, Calif., July 16 Oxygen Biotherapeutics, ... on the first $5 million financing tranche with the Vatea Fund, Segregated ... , For additional details on the agreement, please ... which is available on the SEC website at www.sec.gov and through the ...
Cached Biology Technology:Anthony Hess to Lead SAIC Health Solutions Business Unit 2Anthony Hess to Lead SAIC Health Solutions Business Unit 3Dow AgroSciences, NemGenix Establish New Collaboration in Plant Biotechnology 2
(Date:7/31/2014)... lurks beneath many of the roughly 156,000 gas ... is corrosion in parts of underground gas storage ... contamination of groundwater, a source of drinking water. ... have reported many rapidly corroding gas storage tank ... generally associated with use of gasoline-ethanol blends and ...
(Date:7/31/2014)... make a rational choice to be liberal or conservative? ... a matter of genetics?, Two political scientists from the ... say that neither conscious decision-making nor parental upbringing fully ... right. , A growing body of evidence shows that ... of political differences, the researchers say in the latest ...
(Date:7/31/2014)... known as the Rim Fire was in full fury, ... when it entered the backcountry of Yosemite National Park ... inside the park, the battle began to turn, enacting ... drought can combine to fuel large, severe fires. , ... encountered lands where fire had been used as a ...
Breaking Biology News(10 mins):NIST corrosion lab tests suggest need for underground gas tank retrofits 2Scientists find growing consensus: Political attitudes derive from body and mind 2The Rim Fire 1 year later: A natural experiment in fire ecology and management 2The Rim Fire 1 year later: A natural experiment in fire ecology and management 3The Rim Fire 1 year later: A natural experiment in fire ecology and management 4The Rim Fire 1 year later: A natural experiment in fire ecology and management 5
... are a major cause of disability or premature death in ... already suffered one fragility fracture; they are at twice the ... have not fractured. Nevertheless health care systems around ... leaving them exposed to debilitating and life-threatening secondary fractures. ...
... to 20 percent of veterans returning from Afghanistan and Iraq ... that nearly half these veterans may have a problem so ... it. A new study conducted by Charles W. Wilkinson, Elizabeth ... R. Peskind, all of the VA Puget Sound Health Care ...
... YORK , April 22, 2013 ... report is available in its catalogue: ... Opportunities, 2018 http://www.reportlinker.com/p01162444/India-Biometrics-Market-Forecast-and-Opportunities-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Security_Systems ... new and progressive products in ...
Cached Biology News:New review sets international standards for best practice in fracture liaison services 2Nearly half of veterans found with blast concussions might have hormone deficiencies 2Nearly half of veterans found with blast concussions might have hormone deficiencies 3India Biometrics Market Forecast and Opportunities, 2018 2India Biometrics Market Forecast and Opportunities, 2018 3India Biometrics Market Forecast and Opportunities, 2018 4India Biometrics Market Forecast and Opportunities, 2018 5India Biometrics Market Forecast and Opportunities, 2018 6
Phospho-SEK1/MKK4 (Thr261) Antibody...
Rabbit polyclonal to Warfarin ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule conjugated to KLH...
HSD17B3 Immunogen: HSD17B3 (NP_000188, 29 a.a. ~ 120 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Rabbit polyclonal to 13,14 dihydro 15 keto Prostaglandin E2 ( Abpromise for all tested applications)....
Biology Products: